Koday Merika Treants, Nelson Jorgen, Chevalier Aaron, Koday Michael, Kalinoski Hannah, Stewart Lance, Carter Lauren, Nieusma Travis, Lee Peter S, Ward Andrew B, Wilson Ian A, Dagley Ashley, Smee Donald F, Baker David, Fuller Deborah Heydenburg
Department of Microbiology, University of Washington, Seattle, Washington, United States of America.
Institute for Protein Design, Department of Biochemistry, University of Washington, Seattle, Washington, United States of America.
PLoS Pathog. 2016 Feb 4;12(2):e1005409. doi: 10.1371/journal.ppat.1005409. eCollection 2016 Feb.
Broadly neutralizing antibodies targeting a highly conserved region in the hemagglutinin (HA) stem protect against influenza infection. Here, we investigate the protective efficacy of a protein (HB36.6) computationally designed to bind with high affinity to the same region in the HA stem. We show that intranasal delivery of HB36.6 affords protection in mice lethally challenged with diverse strains of influenza independent of Fc-mediated effector functions or a host antiviral immune response. This designed protein prevents infection when given as a single dose of 6.0 mg/kg up to 48 hours before viral challenge and significantly reduces disease when administered as a daily therapeutic after challenge. A single dose of 10.0 mg/kg HB36.6 administered 1-day post-challenge resulted in substantially better protection than 10 doses of oseltamivir administered twice daily for 5 days. Thus, binding of HB36.6 to the influenza HA stem region alone, independent of a host response, is sufficient to reduce viral infection and replication in vivo. These studies demonstrate the potential of computationally designed binding proteins as a new class of antivirals for influenza.
靶向血凝素(HA)茎部高度保守区域的广谱中和抗体可预防流感感染。在此,我们研究了一种经计算设计的、能与HA茎部相同区域高亲和力结合的蛋白质(HB36.6)的保护效果。我们发现,经鼻递送HB36.6可使受到多种流感病毒株致死性攻击的小鼠获得保护,这与Fc介导的效应功能或宿主抗病毒免疫反应无关。这种设计的蛋白质在病毒攻击前48小时给予6.0 mg/kg的单剂量时可预防感染,在攻击后作为每日治疗药物给药时可显著减轻疾病。在攻击后1天给予10.0 mg/kg的单剂量HB36.6所产生的保护效果明显优于每天两次、连续5天给予10剂奥司他韦。因此,仅HB36.6与流感HA茎部区域的结合,不依赖宿主反应,就足以在体内减少病毒感染和复制。这些研究证明了经计算设计的结合蛋白作为一类新型抗流感病毒药物的潜力。